Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
For clinicians, we hope these findings may prompt a more thoughtful, individualized approach when considering these therapies in higher-risk patients who have both obesity and autoimmune disease. I am excited about the combination of medications for these diseases pairing medicines with known benefits to treat the autoimmune disease with a GLP-1RA, said Sheer
The dosage strength of both medications is also different
Emerging evidence suggests that GLP-1 receptors are not confined to pancreatic islets but are also expressed in cardiomyocytes and vascular endothelial cells (50, 51)
Kosiborod MN, Petrie MC, Borlaug BA et al (2024) Semaglutide in patients with obesity-related heart failure and type 2 diabetes
